Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
https://find-and-update.company-information.service.gov.uk/company/12031776
I think the company runs through the above entity
Poidster,
PROmate COVID-19 is on the list and is OK until 28 February 2022. The labs can continue to use this product. The list of those tests are
https://www.gov.uk/government/publications/covid-19-test-validation-approved-products/medical-devices-regulations-2002-protocol
Hopefully it will move onto the approved products shortly. Unable to find any other info on the other products which we are waiting on being approved.
The docs haven't been updated since 3rd Nov and the whole process has received much criticism.
GM bought shares not long after the vaccine news sent the share price down. he would also have been aware of the payments coming in from DHSC which at that point was not in dispute. He may well have thought phase 2 was a certainty.
I'm sure he isn't concerned about money though and the loss he has made in that share purchase probably won't bother him. i'd like to think he's holding for the long term
private eye are in essence asking for full transparency from the government and the companies involved over PPE and test and trace so that the public can see where all the money went.
it is unfair for novacyt as the accounts are there to see along with the DHSC payments. private eye have been able to stich a lot of info together and come up with that table however there are many more companies which they couldn't add to the table as they didn't have the information.
HarChris,
There is a table with primerdesign at the top of profit margin for Covid first period (15 months). That doesn't look good in print.
There is however an interesting section titled "leaky bucket"
"Baroness Harding told MPs this July included a large bucket of £2.2bn in the form of commercial savings where we were able either to negotiate lower rates or to stop doing non value added work with various partners"
I think we fall into that category.
https://twitter.com/ak_gabba/status/1458528195700043776
might not be up for long. it's 8 pages in the private eye with a short write up on primerdesign
not sure if this has already been posted however I spotted an anounement from ABHI re the CTDA process
https://www.abhi.org.uk/resource-hub/file/13042
Here are some of the results for oxford immunotec
http://www.oxfordimmunotec.com/north-america/news/oxford-immunotec-reports-fourth-quarter-full-year-2019-financial-results/
http://www.oxfordimmunotec.com/north-america/news/oxford-immunotec-reports-first-quarter-2020-financial-results/
http://www.oxfordimmunotec.com/international/news/oxford-immunotec-reports-second-quarter-2020-financial-results/
http://www.oxfordimmunotec.com/international/news/oxford-immunotec-reports-third-quarter-2020-financial-results/
looks like they were keen on their TB diagnostics
https://www.medtechdive.com/news/perkinelmer-buys-oxford-immunotec-591m/593038/
Its all speculation but the appointment of Janet Kidd does look interesting. I'm sure she is well thought of by David due to working together in the past but her recent association most likely during the legalities of a takeover does raise the eyebrows.
close woody. they were all born within 30 miles of the clubs ground. First northern European team to win (all previous winners were from Spain, Portugal or Italy), first UK team and first (only) Scottish team to win.
it's currently man u 0 - man city 2
exmex, yes in the investor power point they are saying
270 highly qualified staff with global
reach currently into 130 countries
https://novacyt.com/wp-content/uploads/2021/06/Novacyt-2020-Full-Year-Results-Strategy-update-Final-website-version-for-29.06.2021-1.pdf
neilrich3, its good to check in on linkedin but as you say not all employees will be on there and not all employees may have updated their profile to include novacyt if they have recently joined.
exmex, in the annual report for year ending 2020 it says employee increase from 110 -> 237
Pillar one testing is still at very high levels
Mar 11,267
Apr 518,418
May 983,035
Jun 1,158,889
Jul 1,463,979
Aug 1,581,886
Sep 1,927,496
Oct 2,202,485
Nov 2,328,320
Dec 2,416,250
2020 Total 14,592,025
Jan 2,560,399
Feb 2,252,080
Mar 2,553,482
Apr 2,514,174
May 2,601,964
Jun 2,645,397
Jul 2,725,576
Aug 2,662,645
Sep 2,718,776
Oct 2,725,364
Nov 374,290
2021 Total 26,334,147
Hopefully the above formatting is OK
they are also looking for more resources in that area
https://novacyt.com/wp-content/uploads/2021/08/Advert-Market-Research-Analyst.pdf
"Collect data on consumers, competitors, identify market trends, pricing/business models, sales and
methods of operation and consolidate information into actionable items, reports and presentations"
Above being one of the points for this position.
we've had plenty of RNS's in the past stating products but sadly lacking any information re sales. it's clear the market wants to understand the revenue said products can add to the company.
I get that they keep re-iterating £100m for this year however we have nothing but speculation for even Q1 2022 and the share price is suffering due to this. Without forward guidance on revenue it looks like we will slide with the odd uptick in share price. Traders/TA dream.
Terrible day for holders just when we thought the bottom was 250p however interesting write up here
https://www.investorschronicle.co.uk/news/2021/11/02/novacyt-shares-pull-back-on-possible-revenue-hit/
"Investors have been quick to grasp the commercial implications. Analysis from BCC Research put the global market value for Covid-19 diagnostics at $60.3bn (£44bn) for 2020. It is anticipated that the market should grow from $84.4bn this year to $195bn by 2027, at a compound annual growth rate of 15 per cent though 2021-27. Numerous assumptions are built into modelling on this basis, so the figures are only indicative, although impossible to ignore. Nevertheless, the number of antigen and antibody tests multiplied rapidly from April 2020 onwards. At that point, the UK recorded a seven-day average of 27,744 tests, but by the following March that figure had risen to 933,234."